Acute Coronary Syndrome - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 115 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Coronary Syndrome - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Acute Coronary Syndrome - Pipeline Review, H2 2015', provides an overview of the Acute Coronary Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Coronary Syndrome
 and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Coronary Syndrome
 products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Coronary Syndrome
 pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome
 pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Coronary Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Acute Coronary Syndrome - Overview 10
Pipeline Products for Acute Coronary Syndrome - Comparative Analysis 11
Acute Coronary Syndrome - Therapeutics under Development by Companies 12
Acute Coronary Syndrome - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Acute Coronary Syndrome - Products under Development by Companies 17
Acute Coronary Syndrome - Companies Involved in Therapeutics Development 18
advanceCor GmbH 18
Arena Pharmaceuticals, Inc. 19
Artery Therapeutics, Inc. 20
Athera Biotechnologies AB 21
Bayer AG 22
Cardiome Pharma Corp. 23
Cerenis Therapeutics Holding SA 24
Esperion Therapeutics, Inc. 25
GlaxoSmithKline Plc 26
Lee's Pharmaceutical Holdings Limited 27
MedImmune, LLC 28
Pfizer Inc. 29
Teva Pharmaceutical Industries Limited 30
The Medicines Company 31
Vitae Pharmaceuticals, Inc. 32
XOMA Corporation 33
Acute Coronary Syndrome - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
4-WF - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AEM-28 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AEM-28-02 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Artpep-2 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Biologics for Acute Coronary Syndrome - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CER-001 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
COR-2 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
COR-3 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
gevokizumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
losmapimod - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
MDCO-216 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MEDI-6012 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PC-mAb - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
PF-06282999 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PMC-6 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PR-15 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
rivaroxaban - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
SD-970 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
temanogrel hydrochloride - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
tirofiban hydrochloride - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
VTP-38443 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ZK-001 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Acute Coronary Syndrome - Recent Pipeline Updates 79
Acute Coronary Syndrome - Dormant Projects 101
Acute Coronary Syndrome - Dormant Projects 101
Acute Coronary Syndrome - Discontinued Products 103
Acute Coronary Syndrome - Product Development Milestones 105
Featured News & Press Releases 105
May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding 105
Apr 23, 2015: Medicure Announces Approval of Expanded Dosing Time For AGGRASTAT 105
Oct 22, 2014: NICE draft guidance recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack 106
Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 107
Aug 29, 2014: Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO in Addressing Critical Medical Needs 107
Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome 109
Jan 16, 2014: FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome 110
Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001 111
Nov 14, 2013: Real-World Data Confirm Clinical Value of Bayer's Novel Oral Anticoagulant Xarelto in Protecting Patients Against Blood Clots 112
Oct 07, 2013: Regulatory Update on Bayer's Xarelto (Rivaroxaban) 2.5 mg in ACS Indication 113
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 114
Disclaimer 115

List of Tables

Number of Products under Development for Acute Coronary Syndrome, H2 2015 10
Number of Products under Development for Acute Coronary Syndrome - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H2 2015 18
Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H2 2015 19
Acute Coronary Syndrome - Pipeline by Artery Therapeutics, Inc., H2 2015 20
Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H2 2015 21
Acute Coronary Syndrome - Pipeline by Bayer AG, H2 2015 22
Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H2 2015 23
Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H2 2015 24
Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H2 2015 25
Acute Coronary Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2015 26
Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 27
Acute Coronary Syndrome - Pipeline by MedImmune, LLC, H2 2015 28
Acute Coronary Syndrome - Pipeline by Pfizer Inc., H2 2015 29
Acute Coronary Syndrome - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 30
Acute Coronary Syndrome - Pipeline by The Medicines Company, H2 2015 31
Acute Coronary Syndrome - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015 32
Acute Coronary Syndrome - Pipeline by XOMA Corporation, H2 2015 33
Assessment by Monotherapy Products, H2 2015 34
Number of Products by Stage and Target, H2 2015 36
Number of Products by Stage and Mechanism of Action, H2 2015 38
Number of Products by Stage and Route of Administration, H2 2015 40
Number of Products by Stage and Molecule Type, H2 2015 42
Acute Coronary Syndrome Therapeutics - Recent Pipeline Updates, H2 2015 79
Acute Coronary Syndrome - Dormant Projects, H2 2015 101
Acute Coronary Syndrome - Dormant Projects (Contd..1), H2 2015 102
Acute Coronary Syndrome - Discontinued Products, H2 2015 103
Acute Coronary Syndrome - Discontinued Products (Contd..1), H2 2015 104